THERAPEUTICSMD, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.86 USD | -0.53% |
|
0.00% | -17.33% |
| Mar. 29 | TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 06 | Knight Therapeutics Announces Launch of Bijuva in Canada | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 906.3 | 656.2 | 358.5 | 151.1 | 52.92 | 25.77 |
| Enterprise Value (EV) 1 | 818.1 | 700.7 | 526.6 | 283.6 | 23.61 | 29.45 |
| P/E ratio | -6.46 x | -3.38 x | -1.82 x | -0.82 x | 0.47 x | -2.28 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 56.3 x | 13.2 x | 5.53 x | 1.74 x | 0.76 x | 19.8 x |
| EV / Revenue | 50.8 x | 14.1 x | 8.12 x | 3.26 x | 0.34 x | 22.6 x |
| EV / EBITDA | -6.3 x | -4.68 x | -3.48 x | -2.3 x | 1.99 x | -3.51 x |
| EV / FCF | -10.1 x | -5.46 x | -5.59 x | -3.8 x | 0.61 x | -0.86 x |
| FCF Yield | -9.95% | -18.3% | -17.9% | -26.3% | 163% | -116% |
| Price to Book | 9.39 x | 71.3 x | -2.93 x | -1.63 x | 1.51 x | 0.89 x |
| Nbr of stocks (in thousands) | 4,758 | 5,424 | 5,925 | 8,499 | 9,467 | 11,452 |
| Reference price 2 | 190.5 | 121.0 | 60.50 | 17.78 | 5.590 | 2.250 |
| Announcement Date | 2/27/19 | 2/24/20 | 3/4/21 | 3/23/22 | 4/7/23 | 3/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 16.1 | 49.65 | 64.87 | 86.95 | 69.96 | 1.302 |
| EBITDA 1 | -129.9 | -149.8 | -151.5 | -123.3 | 11.86 | -8.401 |
| EBIT 1 | -130.2 | -151.2 | -155.5 | -127.4 | 10.66 | -8.523 |
| Operating Margin | -808.85% | -304.56% | -239.76% | -146.48% | 15.24% | -654.61% |
| Earnings before Tax (EBT) 1 | -132.6 | -176.1 | -183.5 | -172.4 | 1.074 | -7.742 |
| Net income 1 | -132.6 | -176.1 | -183.5 | -172.4 | 112 | -10.28 |
| Net margin | -823.74% | -354.8% | -282.9% | -198.29% | 160.08% | -789.4% |
| EPS 2 | -29.47 | -35.75 | -33.29 | -21.66 | 11.95 | -0.9870 |
| Free Cash Flow 1 | -81.4 | -128.3 | -94.25 | -74.65 | 38.54 | -34.19 |
| FCF margin | -505.6% | -258.45% | -145.28% | -85.85% | 55.09% | -2,625.72% |
| FCF Conversion (EBITDA) | - | - | - | - | 325.06% | - |
| FCF Conversion (Net income) | - | - | - | - | 34.41% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/27/19 | 2/24/20 | 3/4/21 | 3/23/22 | 4/7/23 | 3/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25.41 | 18.68 | 19.33 | 28.56 | 20.92 | 1.152 | 0.416 | 0.437 |
| EBITDA | -38.89 | - | - | - | - | - | - | - |
| EBIT 1 | -39.92 | -35.39 | -26.23 | -18.84 | - | 67.01 | -2.667 | -2.472 |
| Operating Margin | -157.13% | -189.48% | -135.67% | -65.97% | - | 5,816.67% | -641.11% | -565.68% |
| Earnings before Tax (EBT) 1 | -47.42 | -42.96 | -49.02 | 112.8 | - | -33.51 | -2.31 | -2.414 |
| Net income 1 | -47.42 | -42.96 | -49.02 | 112.3 | - | 77.7 | -3.603 | -2.414 |
| Net margin | -186.65% | -230% | -253.56% | 393.13% | - | 6,744.97% | -866.11% | -552.4% |
| EPS 2 | -5.500 | -5.000 | -5.690 | 12.39 | -3.130 | 8.230 | -0.3700 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/10/22 | 5/16/22 | 8/15/22 | 11/14/22 | 4/8/23 | 5/15/23 | 8/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 44.5 | 168 | 133 | - | 3.68 |
| Net Cash position 1 | 88.2 | - | - | - | 29.3 | - |
| Leverage (Debt/EBITDA) | - | -0.2967 x | -1.11 x | -1.075 x | - | -0.4378 x |
| Free Cash Flow 1 | -81.4 | -128 | -94.2 | -74.6 | 38.5 | -34.2 |
| ROE (net income / shareholders' equity) | -117% | -330% | 320% | 158% | -3.67% | -23.9% |
| ROA (Net income/ Total Assets) | -45.8% | -39.5% | -43.4% | -45.3% | 5.13% | -7.96% |
| Assets 1 | 289.4 | 445.4 | 422.5 | 380.2 | 2,184 | 129 |
| Book Value Per Share 2 | 20.30 | 1.700 | -20.70 | -10.90 | 3.700 | 2.540 |
| Cash Flow per Share 2 | 33.60 | 29.70 | 13.40 | 7.570 | 4.010 | 0.3800 |
| Capex 1 | 0.22 | 2.45 | 0.21 | 0.03 | - | - |
| Capex / Sales | 1.35% | 4.94% | 0.32% | 0.04% | - | - |
| Announcement Date | 2/27/19 | 2/24/20 | 3/4/21 | 3/23/22 | 4/7/23 | 3/29/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.33% | 21.45M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- TXMD Stock
- Financials TherapeuticsMD, Inc.
